Fortune
In Fortune, BCG’s François Candelon, Maxime Courtaux, Max Männig, and Vinit Patel explore how synthetic biology (syn-bio) startups and industrial incumbents can realize the full potential of syn-bio technologies by teaming together. Startups can leverage incumbents’ domain knowledge to meet product specifications, address regulatory issues, and establish supply chains, while incumbents can reduce their risk of disruption and access technologies they do not currently possess. “Business in the Syn-Bio Age,” the authors explain, “must be a dance between startups and incumbents—not a fight.”